One frequent error is injecting too quickly after cleaning the skin with alcohol
The preclinical findings that there is no tolerance development toward the GLP-1R agonists tested and that the decline in drinking persists after treatment discontinuation suggest clinical applicability ( In conclusion, these preclinical and clinical studies point toward the possibility of using GLP-1R agonists to treat patients with addictions, an interaction that should be elucidated in future studies
Our landmark study confirms that patients can achieve strong outcomes with less medication and underscores the urgency for a more thoughtful and sustainable approach to obesity care
NICE TA875: Semaglutide for managing overweight and obesity
Intensive behavioral therapy provides a potential option for reimbursement of services by dietitians and other health care professionals
*Correspondence: Jens Juul Holst [email protected] This article was submitted to Molecular and Structural Endocrinology, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
